These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28516358)

  • 21. Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.
    Vugmeyster Y; Rohde C; Perreault M; Gimeno RE; Singh P
    MAbs; 2013; 5(3):373-83. PubMed ID: 23529133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of depolymerized holothurian glycosaminoglycan (DHG) on tissue factor pathway inhibitor: in vitro and in vivo studies.
    Nagase H; Enjyoji K; Kamikubo Y; Kitazato KT; Kitazato K; Saito H; Kato H
    Thromb Haemost; 1997 Aug; 78(2):864-70. PubMed ID: 9268186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man.
    Hansen JB; Sandset PM; Huseby KR; Huseby NE; Nordøy A
    Thromb Haemost; 1996 Nov; 76(5):703-9. PubMed ID: 8950777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal state.
    Dahm A; Rosendaal FR; Andersen TO; Sandset PM
    Br J Haematol; 2006 Feb; 132(3):333-8. PubMed ID: 16409298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or blood.
    Knappe S; Gorczyca ME; Jilma B; Derhaschnig U; Hartmann R; Palige M; Scheiflinger F; Dockal M
    Thromb Haemost; 2013 Mar; 109(3):450-7. PubMed ID: 23348798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys.
    Wang W; Wang X; Doddareddy R; Fink D; McIntosh T; Davis HM; Zhou H
    AAPS J; 2014 Jan; 16(1):129-39. PubMed ID: 24287601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
    Fu J; Wang F; Dong LH; Zhang J; Deng CL; Wang XL; Xie XY; Zhang J; Deng RX; Zhang LB; Wu H; Feng H; Chen B; Song HF
    Acta Pharmacol Sin; 2017 May; 38(5):710-718. PubMed ID: 28317872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.
    Benincosa LJ; Chow FS; Tobia LP; Kwok DC; Davis CB; Jusko WJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):810-6. PubMed ID: 10640322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanistic pharmacokinetic-pharmacodynamic modeling of BACE1 inhibition in monkeys: development of a predictive model for amyloid precursor protein processing.
    Liu X; Wong H; Scearce-Levie K; Watts RJ; Coraggio M; Shin YG; Peng K; Wildsmith KR; Atwal JK; Mango J; Schauer SP; Regal K; Hunt KW; Thomas AA; Siu M; Lyssikatos J; Deshmukh G; Hop CE
    Drug Metab Dispos; 2013 Jul; 41(7):1319-28. PubMed ID: 23584887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.
    Ng CM; Loyet KM; Iyer S; Fielder PJ; Deng R
    Eur J Pharm Sci; 2014 Jan; 51():51-8. PubMed ID: 23999033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Preparation and characterization of a McAb against tissue factor pathway inhibitor].
    Yang Y; He X; Li J; He S
    Zhonghua Xue Ye Xue Za Zhi; 1997 Mar; 18(3):118-22. PubMed ID: 15622769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of population PK/PD approach to model the thrombin generation assay: assessment in haemophilia A plasma samples spiked by a TFPI antibody.
    Crépin R; Morin C; Montmartin A; Tardy-Poncet B; Chelle P
    J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):563-580. PubMed ID: 33846873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic and pharmacodynamic modeling of a humanized anti-IL-13 antibody in naive and Ascaris-challenged cynomolgus monkeys.
    Vugmeyster Y; Tian X; Szklut P; Kasaian M; Xu X
    Pharm Res; 2009 Feb; 26(2):306-15. PubMed ID: 18975059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic profiles of a SARS-COV-2 neutralizing antibody BD-604 in cynomolgus monkeys.
    Gao F; Zhang X
    Drug Test Anal; 2021 Oct; 13(10):1727-1734. PubMed ID: 34215019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of novel ultra-sensitive IL-11 target engagement assays to support mechanistic PK/PD modeling for an anti-IL-11 antibody therapeutic.
    Myzithras M; Lin S; Radden L; Hess Kenny C; Cai Z; MacDonald A; Binetti R; Marlow M; Fracasso P; Gibson G; Bartlett C; Hawkins J; Hansel S
    MAbs; 2022; 14(1):2104153. PubMed ID: 35916739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered plasma antigen levels of tissue factor pathway inhibitor during open-heart surgery.
    Sun LB; Utoh J; Kunitomo R; Tsurusaki S; Tagami H; Hirata T; Moriyama S; Okamoto K; Kitamura N
    Surg Today; 2000; 30(2):122-6. PubMed ID: 10664333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of monoclonal antibody against human tissue factor pathway inhibitor on plasma coagulation time].
    Yang Y; He X; Li J; He S
    Hunan Yi Ke Da Xue Xue Bao; 1997; 22(4):297-300. PubMed ID: 9868079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor.
    Kojima T; Gando S; Kemmotsu O; Mashio H; Goda Y; Kawahigashi H; Watanabe N
    J Cardiothorac Vasc Anesth; 2001 Feb; 15(1):60-4. PubMed ID: 11254842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamic effects of low molecular weight heparin in obese subjects following subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor and nitric oxide.
    Mousa SA; Johansen K
    Int Angiol; 2005 Mar; 24(1):40-2. PubMed ID: 15876997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The present status of tissue factor pathway inhibitor.
    Lindahl AK; Sandset PM; Abildgaard U
    Blood Coagul Fibrinolysis; 1992 Aug; 3(4):439-49. PubMed ID: 1420819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.